Pharmatech Presents Preliminary Trial Results at 49th Annual ASH Meeting

Denver, Colorado – December 4, 2007

(Denver, Colorado) – December 4, 2007 – Pharmatech, Inc., a Research Management Organization (RMO), will be presenting preliminary data from two clinical trials evaluating combination therapy to treat patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin’s Lymphoma (NHL) at the American Society of Hematology’s Annual Meeting, to be held December 8-11 in Atlanta, Georgia.

The Principal Investigator of the two studies, Raul Mena, MD of East Valley Hematology and Oncology Medical Group in Burbank, California, will present the two abstracts at 5:30 p.m. Eastern Standard Time on Saturday, December 8, 2007. Abstract 1356, “A Multicenter, Open- Label Study to Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the treatment of Previously Untreated or Treated, Stage II, III, or IV Chronic Lymphocytic Leukemia (CLL)” will be presented on poster board #510-I. Abstract 1354, “A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Pentostatin, Cytoxan, and Rituxan (PCR) in the treatment of Previously Untreated or Treated, Stage III or IV Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) or Bulky Stage II Lymphoma” will be presented on poster board #508-I. To view copies of the abstracts, please visit the ASH web site at www.hematology.org.

About Pharmatech, Inc.

Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients.
For more information about Pharmatech, please visit www.pharmatechoncology.com.